Soares-da-Silva P[au] - Search Results

Year	Number of Results
1981	1
1985	5
1986	3
1987	4
1988	5
1990	12
1991	4
1992	7
1993	9
1994	9
1995	5
1996	7
1997	11
1998	12
1999	10
2000	17
2001	19
2002	21
2003	13
2004	18
2005	17
2006	10
2007	16
2008	23
2009	12
2010	20
2011	16
2012	16
2013	21
2014	15
2015	24
2016	10
2017	11
2018	16
2019	11
2020	12
2021	11
2022	15

1

Effectiveness and safety of opicapone in Parkinson's disease patients with motor fluctuations: the OPTIPARK open-label study.

Reichmann H, Lees A, Rocha JF, Magalhães D, Soares-da-Silva P; OPTIPARK investigators. Reichmann H, et al. Among authors: soares da silva p. Transl Neurodegener. 2020 Mar 4;9(1):9. doi: 10.1186/s40035-020-00187-1. Transl Neurodegener. 2020. PMID: 32345378 Free PMC article. Clinical Trial.

2

Opicapone as Adjunct to Levodopa Therapy in Patients With Parkinson Disease and Motor Fluctuations: A Randomized Clinical Trial.

Lees AJ, Ferreira J, Rascol O, Poewe W, Rocha JF, McCrory M, Soares-da-Silva P; BIPARK-2 Study Investigators. Lees AJ, et al. Among authors: soares da silva p. JAMA Neurol. 2017 Feb 1;74(2):197-206. doi: 10.1001/jamaneurol.2016.4703. JAMA Neurol. 2017. PMID: 28027332 Clinical Trial.

3

Opicapone as an adjunct to levodopa in patients with Parkinson's disease and end-of-dose motor fluctuations: a randomised, double-blind, controlled trial.

Ferreira JJ, Lees A, Rocha JF, Poewe W, Rascol O, Soares-da-Silva P; Bi-Park 1 investigators. Ferreira JJ, et al. Among authors: soares da silva p. Lancet Neurol. 2016 Feb;15(2):154-165. doi: 10.1016/S1474-4422(15)00336-1. Epub 2015 Dec 23. Lancet Neurol. 2016. PMID: 26725544 Clinical Trial.

4

Non-clinical toxicology evaluation of BIA 10-2474.

Hayes AW, Weber K, Moser P, Soares-da-Silva P. Hayes AW, et al. Among authors: soares da silva p. Crit Rev Toxicol. 2021 Jan;51(1):65-75. doi: 10.1080/10408444.2020.1867821. Epub 2021 Feb 2. Crit Rev Toxicol. 2021. PMID: 33528291

5

Nonneuronal dopamine.

Soares-da-Silva P, Vieira-Coelho MA. Soares-da-Silva P, et al. Adv Pharmacol. 1998;42:866-9. doi: 10.1016/s1054-3589(08)60884-4. Adv Pharmacol. 1998. PMID: 9328035 No abstract available.

6

Eslicarbazepine acetate (BIA 2-093).

Almeida L, Soares-da-Silva P. Almeida L, et al. Among authors: soares da silva p. Neurotherapeutics. 2007 Jan;4(1):88-96. doi: 10.1016/j.nurt.2006.10.005. Neurotherapeutics. 2007. PMID: 17199020 Free PMC article. Review.

7

The chemistry of catechol-O-methyltransferase inhibitors.

Learmonth DA, Kiss LE, Soares-da-Silva P. Learmonth DA, et al. Among authors: soares da silva p. Int Rev Neurobiol. 2010;95:119-62. doi: 10.1016/B978-0-12-381326-8.00006-5. Int Rev Neurobiol. 2010. PMID: 21095461 Review.

8

Eslicarbazepine acetate exposure in pregnant women with epilepsy.

Costa R, Magalhães LM, Graça J, Vieira M, Gama H, Moreira J, Rocha JF, Soares-da-Silva P. Costa R, et al. Among authors: soares da silva p. Seizure. 2018 May;58:72-74. doi: 10.1016/j.seizure.2018.04.007. Epub 2018 Apr 10. Seizure. 2018. PMID: 29674237 Free article. Review.

9

Pharmacodynamic evaluation of novel Catechol-O-methyltransferase inhibitors.

Pinheiro SD, Serrão MP, Silva T, Borges F, Soares-da-Silva P. Pinheiro SD, et al. Among authors: soares da silva p. Eur J Pharmacol. 2019 Mar 15;847:53-60. doi: 10.1016/j.ejphar.2019.01.027. Epub 2019 Jan 24. Eur J Pharmacol. 2019. PMID: 30685433

10

Amine neurotransmitters, inflammation and epithelial sodium transport.

Soares-da-Silva P, Cabral JM, Magalhães D, Fraga S, Magro F. Soares-da-Silva P, et al. Exp Physiol. 2016 Apr;101(4):459-64. doi: 10.1113/EP085284. Epub 2015 Dec 14. Exp Physiol. 2016. PMID: 26548358 Free article. Review.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

Search Page

Search Results